Roche’s EU Accelerated Assessment Bid For Tumor Agnostic Entrectinib Backfires
Executive Summary
A decision to yoke together two indications in one EU accelerated assessment filing for the anticancer has backfired on Roche and left the product at even more of a disadvantage compared with Bayer’s Vitrakvi in the tumor-agnostic setting.
You may also be interested in...
NICE Gives Landmark Nod To Bayer's Vitrakvi
Vitrakvi is the first in a new generation of tumor-agnostic drugs to be made available on the NHS after Bayer and NICE finally reached agreement over pricing and access while more data is collected on its clinical effectiveness.
Bayer's Vitrakvi Is EU’s First Tumor-Agnostic Treatment
The German group's cancer drug is the first to be approved for use in Europe for a wide range of tumors. The principal challenge now is to find eligible patients.
Novartis’s Zolgensma Loses EU Accelerated Assessment
Companies pleased at gaining an EU accelerated assessment for a product should be aware that the agency offers no guarantee that they will get to keep it. Novartis’s Zolgensma is one of seven drugs whose review the EMA has taken off the fast track.